Ovarian Cancer

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

Publish Date January 10, 2020

[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.

New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design

By

Sarah Elizabeth Richards

Publish Date January 10, 2020

Some experts say the talc study’s data limitations weaken its impact in the field.

Fertility-Sparing Surgery Achieves Good Oncologic, Obstetric Outcomes in Younger Women With Early-Stage Nonepithelial Ovarian Cancer

By

Susan Moench, PhD, PA-C

Publish Date January 7, 2020

In this first reported prospective study, researchers compared outcomes of fertility-sparing surgery with radical surgery in women with stage I nonepithelial ovarian cancer.

Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer

Publish Date December 27, 2019

Benefit substantial for homologous-recombination deficiency positive tumors with, without BRCA mutations.

CA125 Can Detect Ovarian Cancer in General Practice

Publish Date November 13, 2019

And elevated CA125 indicates higher risk for other cancers, especially in women aged ≥50 years.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer